Abstract: Sets, kits or stocks of anti-myopia contact or spectacle lenses, along with methods for their use, that do not require a clinician to measure peripheral refractive error in the eyes of myopic patients. Extensive surveys have shown that lenses having peripheral powers or defocus set in accordance with central corrective power will cover almost all normal myopes not worse than ?6D central refractive error. In one example, a kit or set of lenses (50, FIG. 15) can have multiple parts or sub-sets (52, 54) each comprising a compartmented container (56a, 56b) with lenses (58a, 58b) arranged according to increments of central corrective power (59a, 59b). The lenses (58a) of the first part (52) have four steps (60a, 61a, 62a, 64a) of peripheral power or defocus to provide therapeutic effect and, while the lenses (58b) of the second part (54) also have four steps (60b, 61b, 62b, 64b), the level of therapeutic effect is higher.

Abstract: Sets, kits or stocks of anti-myopia contact or spectacle lenses, along with methods for their use, that do not require a clinician to measure peripheral refractive error in the eyes of myopic patients. Extensive surveys have shown that lenses having peripheral powers or defocus set in accordance with central corrective power will cover almost all normal myopes not worse than ?6 D central refractive error. In one example, a kit or set of lenses (50, FIG. 15) can have multiple parts or sub-sets (52, 54) each comprising a compartmented container (56a, 56b) with lenses (58a, 58b) arranged according to increments of central corrective power (59a, 59b). The lenses (58a) of the first part (52) have four steps (60a, 61a, 62a, 64a) of peripheral power or defocus to pro vide therapeutic effect and, while the lenses (58b) of the second part (54) also have four steps (60b, 61b, 62b, 64b), the level of therapeutic effect is higher.

Abstract: The present invention relates to pharmaceutical compositions containing lactoferrin, or fragments of it, and their use in the treatment of wounds, particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C-lobe of lactoferrin, or functionally active fragments or variants thereof.

Abstract: The invention provides a use of panthenol or dexpanthenol in the prevention and/or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided.

Abstract: This invention relates to ophthalmic disinfecting and preserving compositions. More particularly, this invention relates to multi-purpose disinfecting solutions [MPDS] suitable for use in or with storage cases for treating multiple-use contact lenses and/or for preserving, disinfecting or packaging of contact and other ophthalmic lenses.

Abstract: The present invention relates to methods of preventing ocular discomfort, improving ocular comfort or ameliorating decrease in ocular comfort during wearing of an ophthalmic device (such as a contact lens), that include the administration of compositions comprising fatty acids, such as omega-3 and/or -6 fatty acids. The present invention also relates to fatty acid compositions suitable for use in the methods of the present invention.

Abstract: Methods and apparatuses are disclosed for improving peripheral vision by positioning the peripheral image points at a pre-determined and precise position relative to the retina to achieve optimal performance according to one or more pre-selected criteria parameters for optimal peripheral vision performance.

Abstract: A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing optical devices and methods comprising the repositioning of peripheral off-axis focal points relative to the retina to produce stimulus for influencing the progression of refractive error while simultaneously controlling the position of the central focal point near to the retina to provide clear central vision and simultaneously providing zones of controlled peripheral defocus and other optical aberrations to improve peripheral vision for select directions of gaze.

Abstract: An instrument and method for characterizing eye-related optical systems, including the live human eye involves scanning an illuminating light beam from a light source and light detector unit from element to element of a beam deflector array of elements arranged laterally across the optical axis of eye. At each successive element the illuminating beam is deflected to form an interrogating beam that is directed into the eye at a peripheral angle that depends upon the lateral location of the deflector element. A return beam is reflected or back-scattered from the cornea and returned via the same deflector element to the light source and detector unit. This allows the interrogating beams to be scanned sufficiently rapidly into the eye to greatly reduce the variation of eye fixation and gaze that accompany other methods of measuring peripheral refraction or aberration of a natural eye.